BioSpace News Archive

CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, began a new era in plasma donations, collecting its first plasma donations using leading-edge plasma collection technology that is expected to significantly reduce average collection time – by approximately one-third – and improve the donor experience.

Xoran Technologies® announces that last month it received FDA 510 clearance for TRON® — a truly mobile, full-body fluoroscopy, computed tomography X-ray system.

Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 24,700 shares of common stock with a grant date of July 29, 2022 for one new employee.

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported recent business progress and financial results for the second quarter June 30, 2022.

PROCEPT® BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, reported unaudited financial results for the quarter ended June 30, 2022.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, reported second quarter 2022 financial results and recent corporate highlights.

CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, August 11, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the second quarter ended June 30, 2022 and to provide a business update.

Apellis Pharmaceuticals, Inc. announced that the company approved the grant of equity awards to two new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, provided business highlights and reported financial results for the second quarter of 2022.

Mersana Therapeutics, Inc. announced that on August 1, 2022, an authorized sub-committee of the Compensation Committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 25,575 shares of its common stock and restricted stock unit awards to acquire an aggregate of 32,475 shares of its common stock, to 8 new employees whose employment commenced in July 2022.